Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy

By D. de Zeeuw, Giuseppe Remuzzi, H. Parving, W. Keane, Zhongxin Zhang, S. Shahinfar, S. Snapinn, M. Cooper, W. Mitch, B. Brenner. Circulation, 2004

770 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Nephrology

View Paper: https://www.semanticscholar.org/paper/472a2fd4689840e3e891dd7cb7901ebbbd1f3020

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. S. Laurent
2. I. Wilkinson
3. J. Cockcroft

In Endocrinology, Diabetes and Metabolism

1. Nur Samsu

In Nephrology

1. Nur Samsu

Citations in the corpus

• Low-Grade Albuminuria and Incidence of Cardiovascular Disease Events in Nonhypertensive and Nondiabetic Individuals: The Framingham Heart Study (2005, neutral): “Optimal blood pressure,* n (%) 764 (49) 405 (52) 359 (46)”
• Expert consensus document on arterial stiffness: methodological issues and clinical applications. (2006, background): “These recommendations were issued long ago before the LIFE and RENAAL trials showed unequivocally that the regression of LVH and albuminuria, respectively, were predictive of the reduction in CV events.(162,163) Since 2003, corresponding to the release of the last guidelines, a large body of evidenc”
• Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment (2021, background): “One of the most important risk factors for the development of kidney disease in diabetic patients is the onset and persistence of proteinuria [132].”